Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | CD38 | P28907 | 1/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.51 |
| ▸ | HTR3B | O95264 | 2/20 | 0.51 |
| ▸ | HTR3A | P46098 | 2/20 | 0.51 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.51 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17231394 | 0.89 | F7 (0.62) | CYP2C9CYP2C19NPC1RAB9AKMT2A | |
| SCHEMBL8513394 | 0.87 | RECQL (0.59) | CYP2C9CYP2C19MEN1KMT2ARECQL | |
| SCHEMBL25780410 | 0.86 | GABRP (0.54) | NPC1RAB9AF7 | |
| SCHEMBL4588413 | 0.86 | PLA2G1B (0.56) | NPC1RAB9AHDAC1 | |
| SCHEMBL3552958 | 0.84 | RXFP1 (0.59) | CYP2C9CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL31043535 | 0.83 | HDAC1 (0.49) | NPC1RAB9AHTR3EHTR3BHTR3A | |
| SCHEMBL29937482 | 0.82 | NPC1 (0.55) | NPC1RAB9AMEN1HCRTR1KMT2A | |
| SCHEMBL884912 | 0.82 | NPC1 (0.55) | NPC1RAB9AMEN1HCRTR1KMT2A | |
| SCHEMBL13134026 | 0.82 | HTR3E (0.61) | NPC1RAB9AF7HTR3EHTR3B | |
| SCHEMBL16108166 | 0.82 | MAPT (0.55) | NPC1RAB9AHTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729031-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-05-20 | — | — | US | claimed |
| EP-2393829-A1 | ACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-12-14 | — | — | EP | claimed |
| US-20110294723-A1 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-01 | — | — | US | claimed |
| WO-2010089544-A1 | ACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-08-12 | — | — | WO | claimed |
| US-9192569-B2 | Formulations for infusion of type B lantibiotics | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-8729031-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2603204-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | Novacta Biosystems Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-05-30 | — | — | US | disclosed |
| EP-1904438-B1 | DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS | NOVO NORDISK AS (DK) | 2012-02-29 | — | — | EP | disclosed |
| WO-2012020219-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| EP-2393829-A1 | ACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294723-A1 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-01 | — | — | US | disclosed |
| EP-1254899-A2 | Piperazine derivatives and their use as anti-inflammatory agents | Schering Aktiengesellschaft (DE) | 2002-11-06 | — | — | EP | disclosed |
| US-6440979-B1 | Aryl isoguanines | EURO-CELTIQUE, S.A. (LU) | 2002-08-27 | — | — | US | disclosed |
| US-6207665-B1 | TO TREAT INFLAMMATORY DISORDERS IN HUMANS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| US-6090816-A | ANTIASTHMA AGENTS | EURO-CELTIQUE S.A. (LU) | 2000-07-18 | — | — | US | disclosed |
| US-6066641-A | PHOSPHODIESTERASES AS MOLECULAR TARGETS FOR ANTI-ASTHMATIC AGENTS | EURO-CELTIQUE S.A. (LU) | 2000-05-23 | — | — | US | disclosed |
| EP-0814809-A4 | ARYL THIOXANTHINES | EURO CELTIQUE SA (LU) | 1998-04-01 | — | — | EP | disclosed |
| EP-0814809-A1 | ARYL THIOXANTHINES | Euroceltique S.A. (LU) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996018399-A1 | ARYL THIOXANTHINES | EURO-CELTIQUE, S.A. (LU) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | SLC5A2, SLC5A11, SPTSSB | CYP2C9 4511/4885CYP2C19 4178/4885NPC1 370/4885 |
| US-20110294723-A1 | Compounds | SLC11A2, SDHA, SDHB | CYP2C9 102/4885CYP2C19 66/4885NPC1 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.